Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 15, 2022

SELL
$5.71 - $13.15 $104,515 - $240,697
-18,304 Closed
0 $0
Q3 2021

Nov 16, 2021

BUY
$8.56 - $27.17 $156,682 - $497,319
18,304 New
18,304 $257,000

Others Institutions Holding EFTR

About eFFECTOR Therapeutics, Inc.


  • Ticker EFTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,452,800
  • Description
  • eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-sma...
More about EFTR
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.